GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stagebiopharmaceutical company developing a pipeline of innovative therapies and biosesesimilars,today announced the company has reached an exclusivecommercialization and license agreement with IntasPharmaceuticals for BAT2506, a golimum...
DetailsGUANGZHOU, China--( BUSINESS WIRE )--Bio-Thera Solutions, Ltd., a fully-integrated pharmaceutical company, today announced that QLETLI ® (格乐立 ® ), a biosesesimilar to Humira ® (adalimumab), is now available in China. QLETLI ® (格乐立 ® ), the first adalimumab biosesesimilar approved by the Chi...
GUANGZHOU, China--( BUSINESS WIRE )--Bio-Thera Solutions, Ltd., a clinical-stage pharmaceutical company, today announced that the China National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application to initiate a Phase I clinical study to compare the phar...
GUANGZHOU, China--( BUSINESS WIRE )--Bio-Thera Solutions, Ltd., a clinical-stage pharmaceutical company, today announced that the China National Medical Products Administration (NMPA) has approved QLETLI ® (格乐立 ® ) for all eligible indications of the reference product, Humira ® (adalimumab)...
